Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ATNM |
---|---|---|
09:32 ET | 6670 | 9.57 |
09:34 ET | 1200 | 9.75 |
09:36 ET | 1000 | 9.9587 |
09:39 ET | 100 | 9.88 |
09:43 ET | 1400 | 9.9399 |
09:45 ET | 650 | 9.7845 |
09:48 ET | 300 | 9.79 |
09:52 ET | 155 | 9.7507 |
09:54 ET | 1330 | 9.76 |
09:56 ET | 200 | 9.83 |
09:57 ET | 842 | 9.78 |
10:06 ET | 420 | 9.8 |
10:08 ET | 710 | 9.66 |
10:12 ET | 3061 | 9.68 |
10:15 ET | 400 | 9.655 |
10:17 ET | 200 | 9.6525 |
10:19 ET | 7732 | 9.695 |
10:24 ET | 2520 | 9.7107 |
10:26 ET | 512 | 9.8037 |
10:30 ET | 100 | 9.8 |
10:32 ET | 409 | 9.777 |
10:33 ET | 100 | 9.798 |
10:35 ET | 500 | 9.7673 |
10:37 ET | 1850 | 9.8148 |
10:39 ET | 110 | 9.845 |
10:42 ET | 1400 | 9.84 |
10:44 ET | 1300 | 9.74 |
10:46 ET | 1700 | 9.75 |
10:48 ET | 200 | 9.715 |
10:50 ET | 500 | 9.61 |
10:53 ET | 1100 | 9.63 |
10:57 ET | 1520 | 9.6525 |
11:00 ET | 200 | 9.63 |
11:06 ET | 432 | 9.7 |
11:08 ET | 1600 | 9.7 |
11:09 ET | 1700 | 9.68 |
11:13 ET | 3625 | 9.71 |
11:18 ET | 400 | 9.71 |
11:20 ET | 216 | 9.73 |
11:22 ET | 1100 | 9.73 |
11:24 ET | 1200 | 9.77 |
11:26 ET | 300 | 9.73 |
11:27 ET | 300 | 9.75 |
11:29 ET | 407 | 9.755 |
11:31 ET | 206 | 9.7565 |
11:42 ET | 400 | 9.78 |
11:49 ET | 9740 | 9.9 |
11:51 ET | 1000 | 9.895 |
11:54 ET | 3415 | 9.9138 |
11:56 ET | 400 | 9.9101 |
11:58 ET | 100 | 9.94 |
12:02 ET | 100 | 9.925 |
12:03 ET | 2700 | 9.93 |
12:05 ET | 166 | 9.9194 |
12:07 ET | 100 | 9.92 |
12:09 ET | 3350 | 9.93 |
12:12 ET | 1000 | 9.91 |
12:16 ET | 1720 | 9.89 |
12:18 ET | 1900 | 9.91 |
12:20 ET | 100 | 9.915 |
12:25 ET | 1049 | 9.9 |
12:30 ET | 381 | 9.89 |
12:34 ET | 1350 | 9.895 |
12:38 ET | 300 | 9.9 |
12:41 ET | 100 | 9.9 |
12:43 ET | 200 | 9.9004 |
12:56 ET | 380 | 9.895 |
12:57 ET | 301 | 9.87 |
12:59 ET | 600 | 9.89 |
01:03 ET | 1000 | 9.8925 |
01:10 ET | 1290 | 9.88 |
01:17 ET | 100 | 9.87 |
01:21 ET | 400 | 9.8647 |
01:24 ET | 1956 | 9.86 |
01:26 ET | 500 | 9.87 |
01:30 ET | 253 | 9.85 |
01:33 ET | 100 | 9.87 |
01:35 ET | 100 | 9.87 |
01:37 ET | 100 | 9.87 |
01:39 ET | 100 | 9.9 |
01:48 ET | 400 | 9.88 |
01:50 ET | 5650 | 9.82 |
01:51 ET | 399 | 9.8245 |
01:55 ET | 331 | 9.84 |
02:02 ET | 1167 | 9.84 |
02:08 ET | 783 | 9.82 |
02:11 ET | 200 | 9.81 |
02:15 ET | 612 | 9.8 |
02:18 ET | 401 | 9.81 |
02:22 ET | 100 | 9.78 |
02:29 ET | 100 | 9.81 |
02:33 ET | 100 | 9.81 |
02:36 ET | 3248 | 9.815 |
02:38 ET | 100 | 9.84 |
02:40 ET | 114 | 9.815 |
02:42 ET | 100 | 9.84 |
02:44 ET | 2000 | 9.8399 |
02:45 ET | 9893 | 9.86 |
02:49 ET | 745 | 9.81 |
02:51 ET | 100 | 9.86 |
02:54 ET | 468 | 9.85 |
02:56 ET | 100 | 9.85 |
02:58 ET | 110 | 9.8483 |
03:00 ET | 7701 | 9.83 |
03:07 ET | 100 | 9.81 |
03:09 ET | 3066 | 9.825 |
03:12 ET | 1550 | 9.83 |
03:14 ET | 1466 | 9.81 |
03:16 ET | 200 | 9.82 |
03:18 ET | 500 | 9.8 |
03:20 ET | 300 | 9.78 |
03:21 ET | 100 | 9.79 |
03:23 ET | 100 | 9.78 |
03:27 ET | 1954 | 9.7767 |
03:30 ET | 275 | 9.77 |
03:32 ET | 400 | 9.8 |
03:34 ET | 400 | 9.825 |
03:36 ET | 209 | 9.8 |
03:38 ET | 300 | 9.83 |
03:41 ET | 1685 | 9.82 |
03:43 ET | 400 | 9.805 |
03:45 ET | 5028 | 9.78 |
03:48 ET | 450 | 9.8 |
03:50 ET | 2921 | 9.825 |
03:52 ET | 2850 | 9.76 |
03:54 ET | 100 | 9.785 |
03:56 ET | 7641 | 9.83 |
03:57 ET | 6333 | 9.77 |
03:59 ET | 26883 | 9.85 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Actinium Pharmaceuticals Inc | 289.8M | -5.7x | --- |
Inozyme Pharma Inc | 288.9M | -3.5x | --- |
Invivyd Inc | 293.3M | -1.3x | --- |
Opthea Ltd | 294.1M | -1.4x | --- |
Ventyx Biosciences Inc | 295.4M | -1.5x | --- |
Rani Therapeutics Holdings Inc | 278.8M | -4.2x | --- |
Actinium Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing targeted radiotherapies to improve survival for people who have failed existing oncology therapies. The Company’s advanced pipeline candidates include Iomab-B (pre-BLA & MAA (EU)) and Actimab-A. Iomab-B is an induction and conditioning agent prior to bone marrow transplant. Actimab-A is a therapeutic agent, have demonstrated potential to extend survival outcomes for people with relapsed and refractory acute myeloid leukemia. The Company focuses on advance Iomab-B for other blood cancers and next generation conditioning candidate Iomab-ACT to improve cell and gene therapy outcomes. The Company holds patent applications including several patents related to the manufacture of the isotope Ac-225 in a cyclotron. Actinium-225 is a potent alpha-particle emitter that has high linear energy transfer capable of killing targeted cancer cells via double-strand breaks in DNA.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $289.8M |
---|---|
Revenue (TTM) | $81.0K |
Shares Outstanding | 29.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.17 |
EPS | $-1.72 |
Book Value | $1.32 |
P/E Ratio | -5.7x |
Price/Sales (TTM) | 3,577.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -61,645.68% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.